Ireland· IE-PA-EU/1/19/1361/010
Skyrizi 55 mg solution for injection in pre-filled syringe
A risankizumab product containing risankizumab, registered in Ireland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Risankizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC18 (risankizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Risankizumab · ATC L04AC18
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of risankizumab costs, country by country.
Normalised to the WHO defined daily dose (1.67 mg), the median price runs from $0.035 in France to $26.21 in Switzerland — a ×755 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Risankizumab · price per daily dose (1.67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$26.21
- FR France$0.035
The record
At a glance
HPRA (Ireland)- Active substance
- RISANKIZUMAB
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Ireland (IE)
- ATC code
- L04AC18
- ATC class
- Risankizumab
- Defined daily dose
- 1.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/19/1361/010
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
75 interactions on record for risankizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Risankizumab · interactions on record
75 records
- 27 severe
- 41 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Risankizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSkyrizi 55 mgAbbVie Deutschland
- CzechiaSKYRIZIAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SwedenSkyrizi 55 mg Injektionsvätska, lösning i förfylld sprutaAbbVie Deutschland GmbH & Co KG
- United StatesSkyriziAbbVie Inc.
- FinlandSkyriziAbbVie Deutschland GmbH&Co.KG
- NetherlandsSkyrizi 150 mg, oplossing voor injectie in voorgevulde penAbbVie Deutschland GmbH & Co. KG
- IcelandSkyriziAbbVie Deutschland GmbH & Co. KG
- SwitzerlandSkyrizi 150 mg, lnjektionslösung in einer FertigspritzeAbbVie AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Skyrizi
- Iceland · Skyrizi
- Liechtenstein · Skyrizi
- Norway · Skyrizi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df1840d4-6e5e-4cfe-bf6d-72f50e71cc9c GET /v1/drugs/df1840d4-6e5e-4cfe-bf6d-72f50e71cc9c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"routes": null,
"source": "hpra",
"atc_all": [
"L04AC18"
],
"strength": null,
"pa_number": "EU/1/19/1361/010",
"substances": [
"RISANKIZUMAB"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "26/04/2019",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about risankizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.